Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 7, 2015, Pages 1853-1864

  Iyer, Vidyashankara ^a   Cayatte, Corinne ^a   Guzman, Bernardo ^a   Schneider Ohrum, Kirsten ^a   Matuszak, Ryan ^a   Snell, Angie ^a   Rajani, Gaurav Manohar ^a   McCarthy, Michael P ^a   Muralidhara, Bilikallahalli ^a  

^a MEDIMMUNE   (United States)

Author keywords

Adjuvants; Emulsions; RSV; Squalene; Stability; Surfactants; Vaccines

Indexed keywords

ALUMINUM SALT; CHOLESTEROL; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 5; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN; SQUALENE; SURFACTANT; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VACCINE; VIRUS FUSION PROTEIN; WATER OIL CREAM; EMULSION; IMMUNOLOGICAL ADJUVANT; OIL; RESPIRATORY SYNCYTIAL VIRUS VACCINE; WATER;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLUIDIZATION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; LIGHT SCATTERING; LIMIT OF DETECTION; MICROFLUIDIZATION; MOUSE; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PH; SHEAR STRESS; SPLEEN CELL; TEMPERATURE STRESS; VIRAL PLAQUE ASSAY; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; EMULSION; IMMUNOLOGY; MEDICINAL CHEMISTRY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SERODIAGNOSIS; TEMPERATURE; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; EMULSIONS; HYDROGEN-ION CONCENTRATION; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OILS; OSMOLAR CONCENTRATION; PARTICLE SIZE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; SQUALENE; TEMPERATURE; WATER;

EID: 84944463299     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1046660     Document Type: Article

References (28)

1. Fenner F. Smallpox: emergence, global spread, and eradication. Hist Philos Life Sci, 1993. 15(3): p. 397-420; PMID:7529932
2. Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsionbased adjuvants for influenza vaccines. Expert Rev Vaccines, 2009. 8(4): p. 483-92; PMID:19348563; http:// dx. doi. org/10. 1586/erv. 09. 5
3. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine, 2010. 28 Suppl 3: p. C25-36; PMID:20713254; http://dx. doi. org/10. 1016/j. vaccine. 2010. 07. 021
4. Channon HJ. The Biological Significance of the Unsaponifiable Matter of Oils: Experiments with the Unsaturated Hydrocarbon, Squalene (Spinacene). Biochem J, 1926. 20(2): p. 400-8; PMID:16743673
5. Huang ZR, YK Lin, JY Fang. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules, 2009. 14(1): p. 540-54; PMID:19169201; http://dx. doi. org/10. 3390/molecules14010540
6. Klucker MF, Dalençon F, Probeck P, Haensler J. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. J Pharm Sci, 2012. 101(12): p. 4490-500; PMID:22941944; http://dx. doi. org/10. 1002/ jps. 23311
7. Suli J, Benísek Z, Eliás D, Svrcek S, Ondrejková A, Ondrejka R, Bajová V. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. Vaccine, 2004. 22(25-26): p. 3464-9; http://dx. doi. org/ 10. 1016/j. vaccine. 2004. 02. 023
8. Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009. 14(9): p. 3286-312; PMID:19783926; http://dx. doi. org/10. 3390/ molecules14093286
9. Podda A, G Del Giudice. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines, 2003. 2(2): p. 197-203; http://dx. doi. org/10. 1586/14760584. 2. 2. 197
10. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine, 2008. 26(26): p. 3209-22; http://dx. doi. org/10. 1016/j. vaccine. 2008. 03. 093
11. Fox CB, J Haensler. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines, 2013. 12(7): p. 747-58; http://dx. doi. org/10. 1586/14760584. 2013. 811188
12. Garcon N, DW Vaughn, AM Didierlaurent. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-inwater emulsion. Expert Rev Vaccines, 2012. 11(3): p. 349-66; http://dx. doi. org/10. 1586/erv. 11. 192
13. Baldridge JR, RT Crane. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods, 1999. 19(1): p. 103-7; PMID:10525445; http://dx. doi. org/10. 1006/meth. 1999. 0834
14. Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC, Kollmann TR, Reed SG, McElhaney JE. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis, 2012. 205(3): p. 466-73; PMID:22147791; http://dx. doi. org/10. 1093/infdis/ jir769
15. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol, 1995. 6: p. 277-96; PMID:7551221; http://dx. doi. org/10. 1007/978-1- 4615-1823-5_10
16. Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol 2004. 17(2): p. 165-81; PMID:15279697; http://dx. doi. org/10. 1089/ 0882824041310513
17. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine, 2013. 31 Suppl 2: p. B209-15; http://dx. doi. org/ 10. 1016/j. vaccine. 2012. 11. 106
18. Cherukuri A, Stokes KL, Patton K, Kuo H, Sakamoto K, Lambert S, Stillman E, Moore ML, Lee S. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing, 2012. 9(1): p. 21; PMID:23031690; http://dx. doi. org/ 10. 1186/1742-4933-9-21
19. Beeler JA, K van Wyke Coelingh. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol, 1989. 63(7): p. 2941-50; PMID:2470922
20. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE Jr, Goleniewska K, et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol, 2009. 83(9): p. 4185-94; PMID:19211758; http://dx. doi. org/10. 1128/JVI. 01853-08
21. Cayatte C, Schneider-Ohrum K, Wang Z, Irrinki A, Nguyen N, Lu J, Nelson C, Servat E, Gemmell L, Citkowicz A, et al. Cytomegalovirus vaccine strain townederived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. J Virol, 2013. 87(20): p. 11107-20; PMID:23926341; http:// dx. doi. org/10. 1128/JVI. 01554-13
22. Chanana GD, BB Sheth. Particle size reduction of emulsions by formulation design. I: Effect of polyhydroxy alcohols. J Parenter Sci Technol, 1993. 47(3): p. 130-4; PMID:8360805
23. Chanana GD, BB Sheth. Particle size reduction of emulsions by formulation design-II: effect of oil and surfactant concentration. PDA J Pharm Sci Technol, 1995. 49(2): p. 71-6; PMID:7780748
24. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLRbased immune adjuvants. Vaccine, 2011. 29(17): p. 3341-55; PMID:20713100; http://dx. doi. org/ 10. 1016/j. vaccine. 2010. 08. 002
25. Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng L, Jin H, Woo J. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A. PLoS One, 2012. 7 (12): p. e51618; http://dx. doi. org/10. 1371/journal. pone. 0051618
26. Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, Hawkins LD, Wack A, O'Hagan DT. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res, 2009. 26(6): p. 1477-85; http://dx. doi. org/10. 1007/s11095-009- 9859-5
27. Lin L, AJ Gerth, SL Peng, CpG DNA redirects classswitching towards "Th1-like" Ig isotype production via TLR9 and MyD88. Eur J Immunol, 2004. 34(5): p. 1483-7; http://dx. doi. org/10. 1002/eji. 200324736
28. Crowe JE, Jr., CY Firestone, BR Murphy. Passively acquired antibodies suppress humoral but not cellmediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol, 2001. 167(7): p. 3910-8; http://dx. doi. org/10. 4049/ jimmunol. 167. 7. 3910